Literature DB >> 15155542

Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study.

Nader Rifai1, Jing Ma, Frank M Sacks, Paul M Ridker, Wendy Jade L Hernandez, Meir J Stampfer, Santica M Marcovina.   

Abstract

BACKGROUND: The relationship of lipoprotein (a) [Lp(a)] concentrations with risk of coronary heart disease needs clarification, especially for threshold values for increased risk and for possible interactions with LDL-cholesterol concentrations and apolipoprotein (a) [apo(a)] size polymorphism. This study was designed to examine the ability of baseline Lp(a) concentration and apo(a) size to predict future severe angina pectoris in apparently healthy men.
METHODS: Baseline Lp(a) concentration and apo(a) size were determined in 195 men who subsequently developed angina and in 195 men who remained free of cardiovascular disease for 5 years.
RESULTS: Cases had higher median Lp(a) concentrations than did controls (30.6 vs 22.5 nmol/L; P = 0.02). Lp(a) concentration was predictive of angina [relative risk (RR) from lowest to highest quintiles: 1.0, 1.5, 1.0, 1.8, and 2.6; P for trend = 0.015]. The increased risk was approximately 4-fold (95% confidence interval, 1.4- to 11-fold) among men who had Lp(a) above the 95th percentile (>158 nmol/L). Men with Lp(a) concentrations in the highest quintile and LDL-cholesterol concentrations >1600 mg/L had a 12-fold increased risk (95% confidence interval, 1.5- to 43-fold). Small apo(a) size isoforms also significantly predicted risk of angina (RR for lowest quintile = 4.1; P for trend = 0.004). When the independent effect of Lp(a) concentration and apo(a) size was assessed by including them in the same multivariate model, only the association between apo(a) size and risk remained significant.
CONCLUSIONS: High Lp(a) predicts risk of angina, and the risk is substantially increased with high concomitant LDL-cholesterol. Small apo(a) size predicts angina with greater strength and independence than Lp(a) concentration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155542     DOI: 10.1373/clinchem.2003.030031

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  29 in total

Review 1.  Lipoprotein (a) measurements for clinical application.

Authors:  Santica M Marcovina; John J Albers
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

Review 2.  Lipoprotein(a): implications for clinical practice.

Authors:  Robert C Block; Thomas A Pearson
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

3.  Differential associations of serum amyloid A and pentraxin-3 with allele-specific lipoprotein(a) levels in African Americans and Caucasians.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Zeynep Ozturk; Wei Zhang; Thomas A Pearson; Lars Berglund
Journal:  Transl Res       Date:  2011-02-05       Impact factor: 7.012

Review 4.  Screening for and management of elevated Lp(a).

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

Review 5.  Lipoprotein (a): a historical appraisal.

Authors:  Karam M Kostner; Gert M Kostner
Journal:  J Lipid Res       Date:  2016-11-07       Impact factor: 5.922

6.  Association of Lp-PLA(2) activity with allele-specific Lp(a) levels in a bi-ethnic population.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Thomas A Pearson; Lars Berglund
Journal:  Atherosclerosis       Date:  2010-04-20       Impact factor: 5.162

7.  Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.

Authors:  Beate R Jaeger; Yvonne Richter; Dorothea Nagel; Franz Heigl; Anja Vogt; Eberhard Roeseler; Klaus Parhofer; Wolfgang Ramlow; Michael Koch; Gerd Utermann; Carlos A Labarrere; Dietrich Seidel
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2009-03

Review 8.  Lipoprotein(a) and atherosclerosis: new perspectives on the mechanism of action of an enigmatic lipoprotein.

Authors:  Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

Review 9.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Authors:  Sebhat Erqou; Stephen Kaptoge; Philip L Perry; Emanuele Di Angelantonio; Alexander Thompson; Ian R White; Santica M Marcovina; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

10.  Lipoprotein(a) level as a predictor of cardiovascular disease and small apoliprotein(a) isoforms in dialysis patients: assay-related differences are important.

Authors:  J Craig Longenecker; Josef Coresh; Michael J Klag; Neil R Powe; Nancy E Fink; Santica M Marcovina
Journal:  Clin Chim Acta       Date:  2008-07-18       Impact factor: 3.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.